Ligand‐Enabled β‐C–H Arylation of α‐Amino Acids Without Installing Exogenous Directing Groups
作者:Gang Chen、Zhe Zhuang、Gen‐Cheng Li、Tyler G. Saint‐Denis、Yi Hsiao、Candice L. Joe、Jin‐Quan Yu
DOI:10.1002/anie.201610580
日期:2017.2
Herein we report acid‐directed β‐C(sp3)‐Harylation of α‐amino acids enabled by pyridine‐type ligands. This reaction does not require the installation of an exogenous directinggroup, is scalable, and enables the preparation of Fmoc‐protected unnatural amino acids in three steps. The pyridine‐type ligands are crucial for the development of this new C(sp3)‐Harylation.
Silver-Catalyzed Decarboxylative Alkynylation of Aliphatic Carboxylic Acids in Aqueous Solution
作者:Xuesong Liu、Zhentao Wang、Xiaomin Cheng、Chaozhong Li
DOI:10.1021/ja306638s
日期:2012.9.5
C(sp(3))-C(sp) bondformations are of immense interest in chemistry and material sciences. We report herein a convenient, radical-mediated and catalytic method for C(sp(3))-C(sp) cross-coupling. Thus, with AgNO(3) as the catalyst and K(2)S(2)O(8) as the oxidant, various aliphatic carboxylic acids underwent decarboxylative alkynylation with commercially available ethynylbenziodoxolones in aqueous solution
Silver-Catalyzed Decarboxylative Trifluoromethylation of Aliphatic Carboxylic Acids
作者:Xinqiang Tan、Zhonglin Liu、Haigen Shen、Pei Zhang、Zhenzhen Zhang、Chaozhong Li
DOI:10.1021/jacs.7b07944
日期:2017.9.13
The silver-catalyzed decarboxylativetrifluoromethylation of aliphatic carboxylicacids is described. With AgNO3 as the catalyst and K2S2O8 as the oxidant, the reactions of aliphatic carboxylicacids with (bpy)Cu(CF3)3 (bpy = 2,2'-bipyridine) and ZnMe2 in aqueous acetonitrile at 40 °C afford the corresponding decarboxylativetrifluoromethylation products in good yield. The protocol is applicable to
The present invention provides compounds of formula (I)
in which y, m, n, R
1
, R
2
and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of protein prenyltransferases including GGTase I and/or RabGGTase. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.